SAB BIOTHERAPEUTICS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
SAB BIOTHERAPEUTICS, INC. (SABS) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $10.90 million as of 2021-10-22, per its 10-K/A filed 2023-04-28.
Discontinued › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2023-04-28
- 2021-10-22: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $10.90M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2021-10-22 | $10.90M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |